• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Thrombotic Microangiopathy Triggered by COVID-19: Case Reports.新冠病毒引发血栓性微血管病：病例报告。
Nephron. 2022;146(2):197-202. doi: 10.1159/000520144. Epub 2021 Nov 22.
2
Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.依库珠单抗用于治疗继发于手术侵袭性应激和出血的严重血栓性微血管病。
Intern Med. 2020;59(1):93-99. doi: 10.2169/internalmedicine.3315-19. Epub 2020 Jan 1.
3
Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.依库珠单抗治疗溃疡性结肠炎相关血栓性微血管病
Clin J Gastroenterol. 2020 Jun;13(3):344-348. doi: 10.1007/s12328-019-01052-z. Epub 2019 Oct 14.
4
Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.依库珠单抗成功治疗继发于脓毒症诱导的弥散性血管内凝血的补体介导血栓性微血管病：一例报告
Medicine (Baltimore). 2017 Feb;96(6):e6056. doi: 10.1097/MD.0000000000006056.
5
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.系统性红斑狼疮和抗磷脂综合征中的继发性血栓性微血管病、补体的作用及依库珠单抗的应用：病例系列及文献复习。
Semin Arthritis Rheum. 2019 Aug;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005. Epub 2018 Dec 4.
6
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.依库珠单抗治疗儿童严重造血干细胞移植相关性血栓性微血管病。
Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25. doi: 10.1016/j.bbmt.2013.12.565. Epub 2013 Dec 25.
7
Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.造血干细胞移植后进行终末补体阻断在未接种脑膜炎球菌疫苗的情况下是安全的。
Biol Blood Marrow Transplant. 2016 Jul;22(7):1337-1340. doi: 10.1016/j.bbmt.2016.03.032. Epub 2016 Apr 7.
8
A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.系统性红斑狼疮相关性血栓性微血管病中依库珠单抗作用的系统评价。
BMC Nephrol. 2020 Jun 30;21(1):245. doi: 10.1186/s12882-020-01888-5.
9
Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.病例报告：成人新冠后多系统炎症综合征和血栓性微血管病。
Front Immunol. 2021 Jun 23;12:680567. doi: 10.3389/fimmu.2021.680567. eCollection 2021.
10
The successful use of eculizumab for treatment of thrombotic microangiopathy in pediatric acute SARSCoV2 infection and multisystem inflammatory syndrome in children.依库珠单抗成功用于治疗儿童急性SARS-CoV-2感染中的血栓性微血管病及儿童多系统炎症综合征。
Haematologica. 2022 Oct 1;107(10):2517-2522. doi: 10.3324/haematol.2022.280603.

引用本文的文献

1
Coronavirus disease 2019-associated thrombotic microangiopathy treated with plasma exchange and antihypertensive therapy in a patient with HIV: A case report with literature review.HIV 感染者新冠病毒病相关血栓性微血管病经血浆置换和降压治疗：病例报告并文献复习。
Medicine (Baltimore). 2023 Oct 13;102(41):e35469. doi: 10.1097/MD.0000000000035469.
2
Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.补体与 COVID-19：三年过去了，我们知道了什么，不知道什么，以及我们应该知道什么。
Immunobiology. 2023 May;228(3):152393. doi: 10.1016/j.imbio.2023.152393. Epub 2023 May 11.
3
Case report: Diarrhea-associated hemolytic uremic syndrome in the Era of COVID-19.病例报告：新冠疫情时代的腹泻相关性溶血尿毒综合征
Front Pediatr. 2022 Oct 31;10:979850. doi: 10.3389/fped.2022.979850. eCollection 2022.
4
Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.新型冠状病毒病相关血栓性微血管病：文献综述。
Int J Mol Sci. 2022 Sep 25;23(19):11307. doi: 10.3390/ijms231911307.
5
COVID-19: A Rare Cause of Hemolytic Uremic Syndrome.新型冠状病毒肺炎：溶血性尿毒症综合征的罕见病因
Cureus. 2022 Aug 13;14(8):e27962. doi: 10.7759/cureus.27962. eCollection 2022 Aug.

新冠病毒引发血栓性微血管病：病例报告。

Thrombotic Microangiopathy Triggered by COVID-19: Case Reports.

机构信息

Nephrology Sechenov First Moscow State Medical University, Moscow, Russian Federation.

Morphology Department, Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation.

出版信息

Nephron. 2022;146(2):197-202. doi: 10.1159/000520144. Epub 2021 Nov 22.

DOI:10.1159/000520144
PMID:34808629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8678244/
Abstract

SARS-CoV-2 causes thrombotic microangiopathy (TMA) through the activation of an alternative and lectin complement pathway. TMA is one of the main reasons for acute kidney injury development in patients with COVID-19. In this study, we present 3 TMA cases with severe kidney injury triggered by SARS-CoV-2. In the absence of other TMA causes, we diagnosed the atypical hemolytic uremic syndrome, triggered by SARS-CoV-2 due to abnormal complement activation. Because of both coagulation factors activation, and the high level of D-dimer in patients with COVID-19, it is crucial to differentiate disseminated intravascular coagulation from TMA. The use of anticomplement therapies such as eculizumab should be considered in refractory cases of progressive COVID-19. Controlled clinical trials are required before a definitive statement can be made.

摘要

SARS-CoV-2 通过激活替代途径和凝集素补体途径引起血栓性微血管病（TMA）。TMA 是 COVID-19 患者急性肾损伤发展的主要原因之一。在本研究中，我们介绍了 3 例由 SARS-CoV-2 引发的严重肾损伤的 TMA 病例。在没有其他 TMA 病因的情况下，由于补体异常激活，我们诊断为 SARS-CoV-2 引发的非典型溶血性尿毒症综合征。由于 COVID-19 患者的凝血因子激活和 D-二聚体水平升高，区分弥散性血管内凝血和 TMA 至关重要。对于进行性 COVID-19 的难治性病例，应考虑使用抗补体疗法，如依库珠单抗。在做出明确声明之前，需要进行对照临床试验。